A number of studies have shown that plumbagin acts on cancer cells as cell cycle inhibitor [24,28,29], cytotoxic agent [27,30,31,32,33,34], angiogenesis inhibitor [35,36], and as a modulator of various cancer-specific pathways (i.e., mediated by NF-κB [37,38] or mitogen activated protein kinases (MAPK) [28,29,39]. Here, WNK2 is linked to cancer.